265 results on '"Leggas, Markos"'
Search Results
2. Neonatal Abstinence Signs during Treatment: Trajectory, Resurgence and Heterogeneity
3. Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent
4. Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy
5. Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors
6. Novel Drug Treatments for Ewing Sarcoma
7. Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects
8. Predicting Student Success Using In-Program Monitoring
9. Abstract CT135: A pilot clinical study of orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors
10. Data from A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies
11. Supplementary Data from A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies
12. Supplementary Figure 1 from Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution
13. Supplementary Table 1 from Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution
14. Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)
15. Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition
16. Abstract 1851: Selective targeting of aberrant ETS transcription factors using uniquely modified mithramycin analogs
17. Abstract CT256: A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors
18. A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors.
19. Stable RNA nanoparticles as potential new generation drugs for cancer therapy
20. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: Lessons learned of the EPR effect and image-guided drug delivery
21. Camptothecins in the Treatment of Primary Brain Tumors
22. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans
23. Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients
24. Interleukin-10 suppression enhances CD8+ T cell responses to checkpoint blockade immunotherapy in Chronic Lymphocytic Leukemia
25. Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments
26. Additional file 1 of Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent
27. Pharmacokinetic Modeling to Assess Factors Affecting the Oral Bioavailability of the Lactone and Carboxylate Forms of the Lipophilic Camptothecin Analogue AR-67 in Rats
28. Factors Affecting the In Vivo Lactone Stability and Systemic Clearance of the Lipophilic Camptothecin Analogue AR-67
29. Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy
30. Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants: Optimization and In Vitro Characterization
31. Reducing signs of aging and increasing lifespan by drug synergy
32. Mithramycin 2′-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy
33. CTNI-75. A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS
34. Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors
35. Validation of an HPLC method for analysis of DB-67 and its water soluble prodrug in mouse plasma
36. Drug Distribution
37. Contributors
38. Abstract A41: Novel mithramycin analogues with improved pharmacologic profile and efficacy in ETS transcription factor-driven tumors
39. Mithramycin analogues with unique mechanism of action in Ewing sarcoma
40. Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants II: Role of Plasma Esterases in Drug Release
41. OleD Loki as a Catalyst for Hydroxamate Glycosylation
42. Enhancing Anti-Tumor Immunity and Responses to Immune Checkpoint Blockade By Suppressing Interleukin-10 in Chronic Lymphocytic Leukemia
43. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine
44. Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition
45. Pharmacokinetic modeling of the blood‐stable camptothecin analog AR‐67 in two different formulations
46. Abstract 2954: Mithramycin analogues disrupt ETS transcription factor DNA binding
47. Bioanalytical method for quantitative determination of mithramycin analogs in mouse plasma by HPLC–QTOF
48. Mithramycin analogues disrupt ETS transcription factor DNA binding
49. Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma
50. Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.